NCT01255332

Helicobacter Pylori Immune Thrombocytopenic Purpura

Efficacy of Helicobacter Pylori Eradication for the 1st Line Treatment of Immune Thrombocytopenic Purpura (ITP) Patients With Moderate Thrombocytopenia

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 26 (estimated)
• Sponsor: Cooperative Study Group A for Hematology · Network
• Sex: All
• Age: 20 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

We designed a study for evaluate the efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenic purpura (ITP) patients with moderate thrombocytopenia. If this eradication treatment is revealed effective on ITP patients with more than 30X109/L of platelet, it would be valuable treatment especially for young ITP patients with mild to moderate thrombocytopenia.

Detailed description

lansoprazole 30mg bid, amoxicillin 1000mg bid and clarithromycin 500mg bid for 7 days. (Jeil Pharm. CO. LTD. will provide lansoprazole.) C13-UBT, at 4 weeks after onset of treatment, to determine eradication

Conditions

• Immune Thrombocytopenic Purpura

Timeline

• Start date: 2010-09-01
• Primary completion: 2011-08-01
• Completion: 2012-08-01
• First posted: 2010-12-07
• Last updated: 2010-12-07

Locations

1 site across 1 country: South Korea